However, tyrosine-phosphorylated p85 was not detectable in lysates of PDGF-treated HER14 cells, suggesting that the vast majority of p85 in the anti-P-Tyr fraction is receptor associated but not phosphorylated on tyrosine residues. Only upon transient overexpression of p85 and PDGF receptor did p85 become tyrosine phosphorylated. These results are consistent with the hypothesis that p85 functions as an adaptor molecule that targets PI 3-kinase to activated growth factor receptors.
The association of a phosphatidylinositol (PI) kinase activity with the v-src and v-ros oncoproteins (24, 43) raised the possibility that such an activity might be involved in cell transformation. This possibility was supported by studies on polyomavirus middle-T-antigen mutants that demonstrated a strong correlation between middle-T-antigen-associated PI kinase activity and transforming potential (18, 53) . Demonstration that a similar PI kinase activity was induced by platelet-derived growth factor (PDGF) treatment of fibroblasts (2, 17, 52) and associated with activated PDGF receptors (9) implicated this activity as a potential participant in the normal mitogenic signaling pathway activated by PDGF. Biochemical characterization of the product of this PI kinase revealed a phospholipid which is phosphorylated at the 3' position of the inositol ring (51) . This finding suggested that PI 3-kinase was part of a signal transduction pathway distinct from the inositol trisphosphate/diacylglycerol pathway mediated by phospholipase C cleavage of PI-4',5'-P2 (reviewed in reference 5). Studies with other mitogenic growth factors have shown that PI 3-kinase is also activated by colony-stimulating factor 1 (36, 39, 47) , insulin (11, 37) , and epidermal growth factor (EGF) (4) . PI 3-kinase activity has also been shown to be associated with the viral oncoproteins v-Abl, v-Crk, and v-Fps (14, 46) . The presence of PI 3-kinase activity in antiphosphotyrosine (anti-P-Tyr) immunoprecipitates of either PDGFtreated or middle-T-antigen-transformed cells has been correlated with the presence of an 85-kDa phosphoprotein (10, 17) . Consistent with this observation, association of PI 3-kinase activity with the PDGF receptor correlates with the association of an 85-kDa protein (12) . Point mutations in the PDGF receptor that abrogate association of PI kinase activity also block association of an 85-kDa protein that is phosphorylated in in vitro kinase assays (19, 20) . These studies suggested that this 85-kDa protein is either a PI 3-kinase or tightly associated with a PI 3-kinase. Purification of PI 3-kinase showed that it is a heterodimer consisting of 85-kDa (p85) and 110-kDa (p110) subunits (6) . Our group and others have recently cloned human, murine, and bovine p85, using different cloning strategies (13, 34, 40) . The amino acid sequence of p85 contains two Src homology region 2 (SH2) domains and one SH3 domain but no apparent ATP-binding site (13, 34, 40) . Efforts to detect PI 3-kinase activity intrinsic to p85 have been unsuccessful (34) , suggesting that pllO contains the catalytic activity. Thus, p85 may be a regulatory subunit of PI 3-kinase. Much evidence suggests that SH2 domains mediate interactions with tyrosine-phosphorylated proteins (1, 26, 28, 30, 32, 40) . SH2 domains have been found in the v-crk oncogene product (29) transduction such as ras GTPase-activating protein (45, 48) and phospholipase C-y (PLC-y) (42, 44) . Studies on PLC--y have shown that it associates with activated growth factor receptors and becomes tyrosine phosphorylated in response to EGF and PDGF treatment (22, 27, 31, 49, 50) . It was subsequently demonstrated that growth factor-induced tyrosine phosphorylation of PLC-y is required for activation of enzymatic activity in vitro (33) and for inositol phospholipid hydrolysis in vivo (21) . The presence of SH2 domains in p85 and the wealth of evidence suggesting a role for PI 3-kinase in a variety of mitogenic signaling pathways implied that PI 3-kinase may be activated by a mechanism similar to that elucidated for PLC-y.
In this study, we have examined the association of p85 with activated growth factor receptors and the tyrosine phosphorylation of p85 in response to growth factor treatment. We demonstrate that p85 interacts with activated EGF and PDGF receptors in cell lysates and in vitro. Either SH2 domain of p85 is sufficient for its interaction with EGF and PDGF receptors. Analysis of these interactions suggests that the stability of the interaction of p85 with EGF and PDGF receptors correlates with the levels of PI 3-kinase activity detected in anti-P-Tyr immunoprecipitates of lysates from HER14 cells treated with EGF and PDGF. However, although growth factor treatment increases the amount of p85 in the anti-P-Tyr fraction of HER14 lysates, we have been unable to demonstrate tyrosine phosphorylation of endogenous p85 in response to PDGF. Tyrosine-phosphorylated p85 was detected only upon transient overexpression of p85 and PDGF receptor. The observation that p85 associates with activated growth factor receptors but does not appear to be phosphorylated on tyrosine residues suggests that it may function as a regulatory subunit of PI 3-kinase or as an adaptor molecule that targets PI 3-kinase to growth factor receptor tyrosine kinases.
MATERIALS AND METHODS
Immunoprecipitation and immunoblotting. HER14 cells are NIH 3T3 (clone 2.2) cells that express the wild-type human EGF receptor (16) . They were grown as previously described (27) . After overnight starvation in Dulbecco modified Eagle medium (DMEM) containing 1% fetal bovine serum, cells were stimulated for 5 min at 37°C with either EGF (250 ng/ml) or PDGF (50 ng/ml) (both from Intergen) in DMEM containing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5) and 1 mg of bovine serum albumin per ml. Cell lysis, immunoprecipitation, and immunoblotting were performed as previously described (27) except that p-nitrophenylphosphate was omitted from the lysis buffer.
Antibodies. Anti-P-Tyr immunoprecipitations were perfor-med with a monoclonal antibody covalently coupled to agarose beads (Oncogene Science), and anti-P-Tyr immunoblots were performed with a rabbit polyclonal antibody. For anti-p85 immunoprecipitations and immunoblots, we generated rabbit polyclonal antibody Ab2l against a glutathione S-transferase (GST)-p85 bacterial fusion protein containing amino acids 265 to 523 of human p85 (40) . This antibody recognizes p85 in immunoprecipitations and immunoblots of purified PI 3-kinase (6) . Two other antibodies were used for p85 immunoprecipitations. One (Ab5l) is directed against a peptide corresponding to amino acids 513 to 531 of human p85 (40) , and the other (AbC) is directed against a C-terminal peptide of human p85 (amino acids 711 to 724 [40] ). Anti-EGF receptor immunoprecipitations were performed with monoclonal antibody 108 (3), and anti-EGF receptor immunoblots were performed with anti-C (27 Competent Eschenichia coli HB101 cells were transformed, and recombinant clones were screened by restriction enzyme analysis and 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of overproduced fusion proteins. The fusion proteins were purified on a large scale by affinity chromatography on glutathioneagarose beads (Sigma) as described previously (41) except that 10 mM dithiothreitol was included in the lysis buffer. The fusion proteins express the following fragments of human p85: N-SH2 (amino acids 321 to 440), C-SH2 (amino acids 614 to 724), and N+C-SH2 (amino acids 321 to 724).
Binding assays. To assay binding of growth factor receptors to GST fusion proteins, 500 p.l of HER14 cell lysate was incubated for 90 min at 4°C with approximately 5 ,ug of fusion protein coupled to glutathione-agarose beads. When inhibitors were added, the HEPES concentration was raised to 200 mM. The beads were washed three times with HNTG (27) , and proteins were separated by 8% SDS-PAGE. Bound proteins were transferred to nitrocellulose and blotted with antibodies as described. For quantitation, appropriate bands were excised from filters and counted in an LKB 1282 Compugamma CS counter.
Transient expression assays. 293 cells were transfected as described previously (7) with human p85 (40) (A) Lysate from -107 cells was immunoprecipitated with either preimmune serum or anti-p85 antiserum (Ab2l). Immunoprecipitates were subjected to 8% SDS-PAGE, transferred to nitrocellulose, and blotted with anti-P-Tyr antibodies. Antibodies were detected by incubation with "2I-protein A followed by autoradiography. Immunoblots were exposed for 12 h at -70'C. The EGF receptor migrates slightly faster and the PDGF receptor migrates slightly slower than does the 180,000-molecular weight marker. (B) Immunoprecipitation and immunoblotting were carried out as described for panel A. Immiunoblots were exposed for 14 h at -70'C. Positions of molecular weight markers are indicated in thousands.
EGF receptors in this cell line. NP-40 (0.5%) completely inhibited PI kinase activity in these immunoprecipitates (lanes 4 and 5), demonstrating that the assay is specifically measuring PI 3-kinase activity (52) .
p85 associates with activatied EGF and PDGF receptors in vivo. We decided to determine whether the disparity between the effects of EGF and PDGF on PI 3-kinase activity in the anti-P-Tyr fraction could be explained by differences in the interaction between p85 and EGF and PDGF receptors. We examined the association of p85 with these growth factor receptors in HER14 cell lysates by assaying for p85-receptor complex formation. An anti-p85 antibody (Ab2l) coimmunoprecipitates tyrosine-phosphorylated proteins that comigrate with activated EGF and PDGF receptors ( Fig. 2A, lanes 5 and 6) . No associated proteins were observed in untreated cells or in immunoprecipitations with preimmune sera ( Fig. 2A-lanes 1 to 4) . Consistent with this finding is the observation that antireceptor antibodies coimmunoprecipitate an-85-kDa protein recognized by anti-p85 antibodies in an immunoblot (Fig. 2B) . The amount of coprecipitated p85 increases upon growth factor treatment (compare lanes 2 and 4 with lanes 1 and 3). In both coprecipitation experiments, the quantity of p85-receptor complex was much greater in lysates of PDGF-treated cells than in lysates of EGF-treated cells (Fig. 2A, lanes 5 and 6;  Fig. 2B, lanes 2 and 4) , despite the presence of nearly 10-fold-more EGF receptors than PDGF receptors in these cells. This disparity in complex formation correlates with the difference in levels of anti-P-Tyr-associated PI 3-kinase VOL. 12, 1992 on activity observed in cells treated with EGF and PDGF (Fig.  1) .
Either SH2 domain of p85 can bind to activated EGF and PDGF receptors in vitro. To determine whether the differences observed in EGF-and PDGF-induced p85-receptor complex formation could be explained by differential binding of the SH2 domains of p85 to EGF and PDGF receptors, we constructed three GST fusion proteins expressing individual SH2 domains of p85 (N-SH2 and C-SH2) and both SH2 *i V?r ! t a . (Fig. 4B) , supporting the notion that receptor tyrosine autophosphorylation is required for interaction with proteins containing SH2 domains (1, 26, 32) . GST alone did not bind to any tyrosine-phosphorylated proteins under these assay conditions (data not shown).
All three fusion proteins also bind to numerous other tyrosine-phosphorylated proteins in lysates from stimulated cells (Fig. 4A) . On the basis of binding experiments with purified EGF receptor kinase (data not shown), it is likely that N-SH2 binds directly to these other tyrosine-phosphorylated proteins. However, at this time we cannot rule out the possibility that some of these proteins bind to N-SH2 indirectly by virtue of their association with activated EGF or PDGF receptors. N+C-SH2 binds to the EGF receptor and other tyrosine-phosphorylated proteins more efficiently than does N-SH2 by itself (Fig. 4A) . This may be a consequence of the fact that N+C-SH2 contains twice as many binding sites for tyrosine-phosphorylated proteins as does either N-SH2 or C-SH2 alone; alternatively, the conformation of N+C-SH2 may differ from those of N-SH2 and C-SH2 such that it interacts more favorably with tyrosine-phosphorylated proteins.
Phosphotyrosine specifically and differentially inhibits receptor-SH2 interactions. Since interaction of various SH2-containing proteins with growth factor receptors is dependent on receptor tyrosine phosphorylation (1, 12, 25, 26, 32), we reasoned that P-Tyr might competitively inhibit receptor- Bound proteins were subjected to 8% SDS-PAGE and immunoblotted as described for Fig. 2 . Thirty microliters of HER14 lysate was analyzed in lanes 10 to 12. In panel B, it should be noted that the anti-EGF receptor antibodies are much more efficient in immunoblotting than are the anti-PDGF receptor antibodies, resulting in a much stronger signal in the anti-EGF receptor immunoblot. Immunoblots were exposed for 12 h at -70°C. Positions of molecular weight standards are indicated in thousands. SH2 interactions. It has recently been shown that P-Tyr can partially inhibit the binding of the c-abl SH2 domain to cellular tyrosine-phosphorylated proteins (30) . We tested this hypothesis by performing fusion protein binding assays in the presence of increasing concentrations of P-Tyr (Fig.  5) . Quantitation revealed that the half-maximal inhibitory concentration of P-Tyr for PDGF receptor binding is approximately 24 mM, or about 12 times greater than that for EGF receptor binding (Fig. 6 ). This inhibition is specific-to P-Tyr, as tyrosine, phosphoserine, and phosphothreonine had no effect on binding (data not shown). We also noted that the binding of the EGF receptor to N-SH2 was more sensitive to increasing salt concentration. For example, 500 mM LiCl completely inhibited the binding of N-SH2 to EGF receptors but reduced N-SH2 binding to PDGF receptors by only 50% (data not shown). These results suggest that p85 itself binds to tyrosine-phosphorylated EGF receptors with lower affinity than it binds to tyrosine-phosphorylated PDGF receptors. Binding was normalized to binding in the absence of inhibitor.
p85 is associated with the anti-P-Tyr fraction in lysates of HER14 cells treated with PDGF. To determine whether PI 3-kinase-associated p85 was present in the anti-P-Tyr fraction of HER14 cell lysates, we immunoblotted anti-P-Tyr immunoprecipitates with anti-p85 antibodies. EGF and PDGF treatment of HER14 cells increased the amount of p85 present in the anti-P-Tyr fraction (Fig. 7, lanes 7 to 9) . PDGF did so to a much greater extent than did EGF, consistent with the magnitude of PDGF and EGF effects on anti-P-Tyrassociated PI 3-kinase activity (Fig. 1) .
Tyrosine-phosphorylated p85 is not detectable in lysates of HER14 cells treated with PDGF. In view of the relatively weak effects of EGF on receptor-associated PI 3-kinase activity ( Fig. 1) and receptor-p85 complex formation (Fig. 2) , we chose to focus on the effect of PDGF on p85 phosphorylation. Anti-P-Tyr immunoblotting of anti-p85 immunoprecipitates demonstrated association of the activated PDGF receptor with p85 but failed to detect tyrosine-phosphorylated p85 (Fig. 2A) . Similar results were obtained with three different polyclonal rabbit antibodies against p85; all of these antibodies were able to coimmunoprecipitate tyrosine-phosphorylated PDGF receptor, but none was able to immunoprecipitate tyrosine-phosphorylated p85 detectable in an anti-P-Tyr immunoblot (Fig. 8, lanes 1 to 6) antibody (AbS1) also failed to reveal the presence of tyrosine-phosphorylated p85, although low levels of serine and threonine phosphorylation were detected (data not shown). In addition, secondary immunoprecipitation of anti-P-Tyr eluates from 32Pi-labeled lysates demonstrated that anti-PTyr-associated p85 is phosphorylated at extremely low stoichiometry (data not shown).
p85 is phosphorylated on tyrosine in cells that transiently overexpress p85 and PDGF receptor. To investigate the effect of overexpression on p85 tyrosine phosphorylation, we coexpressed p85 and PDGF receptor transiently in 293 cells. Anti-P-Tyr blotting of lysates and anti-p85 blotting of antip85 immunoprecipitates demonstrated PDGF receptor and p85 expression, respectively (Fig. 9A and C) . No tyrosinephosphorylated proteins were detected in anti-p85 immunoprecipitates of control lysates or lysates from cells overexpressing p85 alone (Fig. 9B, lanes 1 to 4) . Anti-p85 antibodies coprecipitated PDGF receptor from lysates of cells overexpressing PDGF receptor alone; however, no endogenous tyrosine-phosphorylated p85 was detected (lanes 5 and 6). Upon overexpression of both p85 and PDGF receptor, tyrosine-phosphorylated p85 was detected in antip85 immunoprecipitates (lanes 7 and 8).
Transient overexpression of p85 abrogates anti-P-Tyr-associated PI 3-kinase activity. To assess the effect of p85 overexpression on anti-P-Tyr-associated PI 3-kinase activity, we performed PI 3-kinase assays on anti-P-Tyr immunoprecipitates of lysates from 293 cells overexpressing either PDGF receptor alone or both PDGF receptor and p85 (Fig.  10) . The anti-P-Tyr fraction from cells transfected with vector alone did not contain significant amounts of PDGFinducible PI 3-kinase activity (lanes 1 and 2) . Upon overexpression of PDGF receptor, ligand-dependent induction of anti-P-Tyr-associated activity was observed (lanes 3 and 4). Concomitant overexpression of PDGF receptor and p85 reduced PI 3-kinase activity in the anti-P-Tyr fraction to levels observed in control transfections (lanes 5 and 6), as did coexpression of PDGF receptor with a fragment of p85 consisting of both SH2 domains (lanes 7 and 8). Anti-p85 antibodies immunoprecipitate PI 3-kinase activity. To demonstrate that our anti-p85 antibodies recognize PI 3-kinase and not just free p85, we assayed HER14 anti-p85 immunoprecipitates for PI 3-kinase activity. The anti-p85 antibodies AbSi and AbC both precipitated PI 3-kinase activity (Fig. 11A, lanes 5 to 8) , whereas preimmune serum did not (lanes 3 and 4) . Activity was present in immunoprecipitates of lysates from quiescent cells as well as PDGFtreated cells. No significant increase in immunoprecipitable activity was observed upon PDGF treatment (compare lanes 5 and 7 with lanes 6 and 8; the difference in activity between lanes 5 and 6 was not reproducible). The amount of activity present in anti-p85 immunoprecipitates was considerably less than that observed in the anti-P-Tyr fraction of PDGFtreated cells (lane 2).
In an effort to correlate p85 levels with PI 3-kinase activity, the same samples that were assayed for activity were immunoblotted with anti-p85 antibodies (Fig. llB) . Surprisingly, much more p85 was detected in anti-p85 immunoprecipitates than in the anti-P-Tyr fraction (compare lanes 5 to 8 with lane 2), despite the fact that the anti-P-Tyr fraction contains more PI 3-kinase activity (Fig. 11A) . (Fig. 4) domains of p85 are sufficient to mediate interactions with activated PDGF receptors in vitro. The observation that overexpression of either full-length p85 or a fragment consisting of both SH2 domains of p85 blocks PDGF-induced association of PI 3-kinase activity with the anti-P-Tyr fraction in living cells (Fig. 10) suggests that the SH2 domains of p85 are also sufficient for p85-receptor complex formation in vivo, although a role for the region between the N-terminal and C-terminal SH2 domains in p85-receptor interactions cannot formally be ruled out.
Despite the observation that p85 forms stable complexes with activated PDGF receptors in vivo (Fig. 2) , we were unable to demonstrate tyrosine phosphorylation of p85 in response to PDGF. Three different anti-p85 antibodies failed to detect tyrosine-phosphorylated p85 in lysates of PDGFtreated HER14 cells (Fig. 8) , although they were able to immunoprecipitate tyrosine-phosphorylated p85 (Fig. 9B) and PI 3-kinase activity (Fig. 11A) . In vitro kinase assays demonstrate that an 85-kDa protein in the anti-P-Tyr fraction of PDGF-treated HER14 cells can be phosphorylated; this protein is specifically immunoprecipitated by anti-p85 antibodies (data not shown). This finding together with the fact that tyrosine-phosphorylated p85 is detectable only upon p85 overexpression (Fig. 9B) suggests either that PDGF induces tyrosine phosphorylation of endogenous p85 at very low stoichiometry or that p85 is an efficient substrate for protein tyrosine phosphatases.
The absence of a tyrosine-phosphorylated 110-kDa protein in anti-p85 immunoprecipitates of PDGF-treated HER14 cells (Fig. 8) suggests that pllO may also not be substantially tyrosine phosphorylated in the steady state. Anti-p85 immunoprecipitates of [ 5S]methionine-labeled HER14 cell lysates revealed the presence of a 110-kDa protein that could be p110, but numerous other proteins were also present in the immunoprecipitate. It is noteworthy that the various components which are essential for the activity and regulation of PI 3-kinase are not yet determined.
The possibility that endogenous p85 is not tyrosine phosphorylated in response to PDGF raises the question of how PI 3-kinase is activated upon growth factor treatment. The increase in PI 3-kinase products observed in intact cells upon PDGF treatment (2) could represent activation; alternatively, it may simply reflect localization of constitutive PI 3-kinase activity to the cell membrane, where PI 3-kinase substrates are more abundant. It is noteworthy that PI 3-kinase assays of anti-p85 immunoprecipitates do not demonstrate a major increase in activity after PDGF treatment (Fig. 11A) . However, attempts to correlate p85 levels with PI 3-kinase activity show that the relatively small amount of p85 associated with the anti-P-Tyr fraction is associated with a disproportionate amount of PI 3-kinase activity (Fig. 11) . A definitive determination of whether PI 3-kinase is activated by PDGF awaits the generation of specific antibodies against the presumptive catalytic pllO subunit.
Our data suggest that endogenous p85 associates readily with but is not tyrosine phosphorylated by activated PDGF receptors. Only when overexpressed does p85 become tyrosine phosphorylated in response to PDGF. Thus, p85 may not be a good substrate for the PDGF receptor tyrosine kinase. It is possible that p85 serves as an adaptor molecule or a regulatory subunit of PI 3-kinase whose function is to target the catalytic moiety of PI 3-kinase to activated tyrosine kinases. It will be interesting to determine whether the pllO subunit is tyrosine phosphorylated in response to PDGF and other growth factors and whether the presence of p85 enhances the phosphorylation of p110. Other molecules that contain SH2 and SH3 domains but have no apparent catalytic activity and no known function, such as Nck (23) and the product of the c-crk proto-oncogene (28, 29) , may have similar functions. It will be of great interest to identify the molecules that associate with these putative adaptor molecules, determine whether they serve as substrates for growth factor receptor tyrosine kinases, and elucidate their potential roles in cellular signaling.
